Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | CTSD | P07339 | 1/20 | 0.34 |
| ▸ | CTSL | P07711 | 1/20 | 0.34 |
| ▸ | CTSB | P07858 | 1/20 | 0.34 |
| ▸ | CTSS | P25774 | 1/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.33 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.33 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.33 |
| ▸ | ELANE | P08246 | 1/20 | 0.32 |
| ▸ | ACACB | O00763 | 1/20 | 0.32 |
| ▸ | GBA1 | P04062 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3187773 | 0.89 | HDAC6 (0.36) | HDAC6HDAC1HDAC2CA12CA1 | |
| SCHEMBL13824284 | 0.88 | DGAT1 (0.38) | HDAC6HDAC1HDAC2CA12CA1 | |
| SCHEMBL7023795 | 0.88 | CA14 (0.39) | HDAC6HDAC1HDAC2CA12CA1 | |
| SCHEMBL14789144 | 0.88 | HDAC6 (0.35) | HDAC6HDAC1HDAC2CA12CA1 | |
| SCHEMBL1925237 | 0.86 | HDAC6 (0.34) | HDAC6HDAC1HDAC2CA12CA1 | |
| SCHEMBL17837044 | 0.86 | HDAC6 (0.34) | HDAC6HDAC1HDAC2CA14ELANE | |
| SCHEMBL5001089 | 0.84 | CA12 (0.55) | HDAC6HDAC1HDAC2CA12CA1 | |
| SCHEMBL14311330 | 0.84 | CA12 (0.38) | HDAC6HDAC1HDAC2CA12CA1 | |
| SCHEMBL25980823 | 0.84 | CA14 (0.33) | HDAC6HDAC1HDAC2CA12CA1 | |
| SCHEMBL15487077 | 0.83 | CA12 (0.37) | HDAC6HDAC1HDAC2CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3771709-A1 | CREATINE PRODRUGS, COMPOSITIONS AND METHODS OF USE THEREOF | Farmington Pharma Development (US) | 2021-02-03 | — | — | EP | disclosed |
| US-20170342039-A1 | CREATINE PRODRUGS, COMPOSITIONS AND METHODS OF USE THEREOF | Farmington Pharma Development | 2017-11-30 | — | — | US | disclosed |
| US-8901353-B2 | Polyimide precursor, polyimide, and liquid crystal aligning agent | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2014-12-02 | — | — | US | disclosed |
| US-20120088888-A1 | POLYIMIDE PRECURSOR, POLYIMIDE, AND LIQUID CRYSTAL ALIGNING AGENT | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2012-04-12 | — | — | US | disclosed |
| US-20110257014-A1 | 1-(Heteroaryl)pyrazol-4-ylacetic acids, processes for their preparation and their use as herbicides and plant growth regulators | BAYER CROPSCIENCE AG (DE) | 2011-10-20 | — | — | US | disclosed |
| WO-2011115080-A1 | POLYAMIC ACID ESTER LIQUID CRYSTAL ALIGNMENT AGENT, AND LIQUID CRYSTAL ALIGNMENT FILM USING SAME | 日産化学工業株式会社 (JP) | 2011-09-22 | — | — | WO | disclosed |
| CN-1795202-B | Metal chelate complexes immobilized on solid supports for peptide preparation | APLAGEN GMBH | 2010-05-26 | — | — | CN | disclosed |
| CN-1795202-A | Metal chelate complexes immobilized on solid supports for peptide preparation | APLAGEN GMBH (DE) | 2006-06-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170342039-A1 | CREATINE PRODRUGS, COMPOSITIONS AND METHODS OF USE THEREOF | CKMT1A; CKMT1B, SLC2A1, SLC29A2 | HDAC6 3507/4885HDAC1 3377/4885HDAC2 3317/4885 |
| US-20110257014-A1 | 1-(Heteroaryl)pyrazol-4-ylacetic acids, processes for their preparation and their use as herbicides and plant growth regulators | DDT, HPD, DDC | HDAC6 2426/4885HDAC1 2088/4885HDAC2 1904/4885 |
| US-20120088888-A1 | POLYIMIDE PRECURSOR, POLYIMIDE, AND LIQUID CRYSTAL ALIGNING AGENT | PUF60, F13A1, F12 | HDAC6 3529/4885HDAC1 3429/4885HDAC2 3785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.